Influencing factors of the comorbidity between inflammatory bowel disease and depression
10.3969/j.issn.1006-2483.2025.01.003
- VernacularTitle:炎症性肠病与抑郁障碍共病影响因素研究
- Author:
Yiting CAO
1
;
Yuying ZHOU
1
;
Jiahui LAO
2
;
Fang TANG
2
Author Information
1. School of Public Health , Shandong Second Medical University , Weifang , Shandong 261053 , China
2. Center for Big Data Research in Health and Medicine , Shandong Province Qianfoshan Hospital , Shandong Data Open Innovative Application Laboratory , Jinan , Shandong 250014 , China
- Publication Type:Journal Article
- Keywords:
Inflammatory bowel disease;
Depression;
Case-control study
- From:
Journal of Public Health and Preventive Medicine
2025;36(1):13-17
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the influencing factors associated with the comorbidity of inflammatory bowel disease (IBD) and depression. Methods A case-control study was conducted based on the “Healthcare Big Data Platform” of a tertiary class-A comprehensive hospital in Shandong Province. IBD comorbid with depression was served as the case group and IBD without depression was served as the control group. Propensity score matching (PSM) was performed by matching the case group with the control group in a ratio of 1:2 according to the age and gender of the patients. Conditional logistic regression model was used to explore the influencing factors associated with the comorbidity of IBD and depression. Results A total of 405 patients with IBD were enrolled in this study, including 270 patients without depression and 135 patients comorbid with depression. The results of conditional logistic regression showed that the use of immunosuppressants (OR=2.84, 95% CI: 1.00-8.07) and glucocorticoids (OR=2.05, 95% CI: 1.17-3.58), dementia (OR=5.20, 95% CI:1.59-17.05), cardiovascular disease (OR=3.58, 95% CI: 1.84-6.98) and cancer (OR=2.63, 95% CI: 1.16-5.95) were associated with the comorbidity of depression and IBD. Conclusion Attention should be paid to the use of immunosuppressants and glucocorticoids in the population of IBD comorbid with depression, and the coexistence of physical diseases such as dementia, cardiovascular disease and cancer. Early prevention and targeted treatment measures should be taken for high-risk populations to reduce their risk of depression and improve their quality of life and health.
